The OD was Dr Mahboobi who took the time to thoroughly examine my eyes and make recommendations! The office was clean, modern and professional. I had a great experience and highly recommend them.
— Perfecto Ramos
CMV Retinitis: What You Need to Know to Protect Your Vision
Who Is at Risk?
Certain medical conditions and treatments significantly increase the risk of developing CMV retinitis. Knowing whether you fall into a high-risk group is an important step toward getting appropriate preventive care and screening.
The most well-known risk group is people living with HIV, particularly those with advanced AIDS and very low CD4+ T-cell counts. CD4+ T-cells are a type of immune cell measured to assess immune health. CMV retinitis rarely occurs when CD4+ counts are above 100 cells per microliter and becomes a meaningful risk when counts fall below 50 cells per microliter.
Patients who are not receiving antiretroviral therapy, those whose treatment has not been effective, and those with very high HIV viral loads face the greatest risk. A history of other opportunistic infections, meaning infections that take advantage of a weakened immune system, also increases the likelihood of CMV retinitis.
People who have received solid organ transplants take immunosuppressive medications to prevent their body from rejecting the new organ. These medications intentionally weaken the immune system, creating an opening for cytomegalovirus. The risk is especially high when a patient who has never been exposed to CMV receives an organ from a donor who carries the virus.
Several other groups can be at risk when immune defenses are severely reduced. These include patients undergoing chemotherapy for cancer, people taking strong immunosuppressive medications for autoimmune conditions, and newborns with congenital immune deficiencies.
- Patients undergoing chemotherapy or bone marrow transplantation
- People on long-term high-dose immunosuppressive therapy for autoimmune diseases
- Newborns with congenital immune deficiencies
- Elderly individuals with significant age-related immune decline
If you are taking any medication that suppresses immune function, speak with both your prescribing physician and a retina specialist about your eye health.
Symptoms of CMV Retinitis
CMV retinitis does not always announce itself with obvious warning signs, especially in its early stages. Because vision loss from this infection can be permanent, knowing what to look for and acting quickly is essential.
In many cases, CMV retinitis causes no symptoms at all in the beginning. When early symptoms do appear, the most common complaint is new floaters, the small spots, threads, or cobweb-like shapes that drift across the field of vision. Floaters alone are not always cause for alarm, but in someone with a weakened immune system, new or worsening floaters should be evaluated promptly by a retina specialist.
As CMV retinitis spreads across more of the retina, additional symptoms may develop. A shadow or dark area may appear in the side (peripheral) vision and gradually grow larger. Blurred vision and flashes of light can also occur. A veil or curtain effect across part of the visual field is a particularly serious warning sign.
If the infection reaches the macula, the central part of the retina responsible for sharp detail and color vision, significant and potentially permanent central vision loss can result. The macula and the optic nerve are the two most critical structures at risk in advancing CMV retinitis.
Certain symptoms should be treated as a medical emergency. If you have a weakened immune system and experience any of the following, seek care from a retina specialist or go to the emergency room immediately. Do not wait to see if symptoms improve on their own.
- A sudden increase in floaters
- Flashes of light in one or both eyes
- A shadow, curtain, or dark veil moving across your vision
- Sudden loss of vision in one eye
These symptoms may indicate rapidly progressing CMV retinitis or a retinal detachment, both of which require urgent treatment to preserve vision.
How CMV Retinitis Is Diagnosed
Accurate diagnosis requires a careful examination of the retina by a specialist with experience in infectious and inflammatory eye diseases. Early identification, even before symptoms appear, gives patients the best chance of protecting their vision.
The primary diagnostic tool is a comprehensive dilated eye examination. Dilating the pupil allows the retina specialist to see the retina clearly using specialized lenses and instruments. The characteristic appearance of CMV retinitis, with its distinctive pattern of white necrotic tissue and bleeding, is often recognizable on examination. The location and extent of involvement are carefully documented to guide treatment planning and track changes over time.
Because CMV retinitis can be present without any symptoms, regular screening examinations are critical for people in high-risk groups. Patients with HIV and CD4+ counts below 50 cells per microliter should have eye examinations at least every three months. Catching the infection before significant damage occurs is the most effective way to preserve usable vision.
Our retina team uses a full suite of diagnostic imaging to evaluate and monitor the retina in detail. These tools help detect the extent of damage, identify complications, and track the response to treatment over time.
- Optical coherence tomography (OCT): creates detailed cross-sectional images of retinal layers
- Fluorescein and indocyanine green (ICG) angiography: uses injected dye to visualize blood flow and vascular changes in the retina
- Color fundus photography: captures high-resolution images of the retina for documentation and comparison
- B-scan echography: uses sound waves to evaluate structures inside the eye when the retina is not clearly visible
In cases where the diagnosis is uncertain, a small sample of fluid from inside the eye can be tested for cytomegalovirus DNA using a highly sensitive technique called polymerase chain reaction (PCR).
Treatment for CMV Retinitis
Treating CMV retinitis requires a coordinated approach that targets the virus directly and addresses the underlying immune condition. Our visiting retina specialists work closely with each patient's medical team to build a personalized treatment plan.
Systemic antiviral medications, meaning those taken by mouth or delivered through an IV to treat the whole body, are the foundation of CMV retinitis treatment. Several FDA-approved antiviral options are available, including ganciclovir, valganciclovir, foscarnet, and cidofovir. Oral valganciclovir is the most commonly used today because of its convenience and strong effectiveness.
Treatment typically begins with a higher induction dose given for two to three weeks to bring the infection under control, followed by a lower maintenance dose to prevent recurrence. Treating the whole body also helps protect other organs that cytomegalovirus can affect. Blood tests are performed regularly during treatment because some antivirals can affect blood cell counts or kidney function.
A retina specialist may also deliver antiviral medication directly into the eye through an intravitreal injection, an injection into the gel-filled space inside the eye called the vitreous. Ganciclovir and foscarnet can both be administered this way. Intravitreal injections are often used alongside systemic therapy during the early stages of treatment, especially when the infection is near the macula or optic nerve and requires the fastest possible response.
Treatment choices are individualized based on the location and severity of the retinitis, the patient's overall immune status, and how well the infection is responding to initial therapy.
For patients with HIV, the single most important long-term strategy is restoring immune function through highly active antiretroviral therapy (HAART). The widespread use of HAART has dramatically reduced the incidence of CMV retinitis and significantly cut the risk of disease progression. When CD4+ T-cell counts rise and are sustained above safe levels, the risk of CMV reactivation falls substantially, and maintenance antiviral therapy may eventually be discontinued under careful medical supervision.
For transplant recipients and others on long-term immunosuppression, the goal is to find the appropriate balance between preventing organ rejection and reducing infection risk. This requires close collaboration between the retina team and the patient's transplant or primary care physicians.
Living With CMV Retinitis
Managing CMV retinitis is an ongoing process that extends well beyond the initial treatment phase. Our team is committed to supporting patients through every stage of their care, from diagnosis through long-term monitoring.
During the induction phase, patients are seen frequently to confirm that the borders of the infection are stabilizing. Once the active infection is controlled, follow-up appointments continue at regular intervals to watch for any signs of reactivation. Even after successful treatment, the virus remains in the body and can reactivate if immune function declines again.
It is important to understand that retinal tissue destroyed by CMV retinitis does not regenerate. Vision lost before treatment begins is typically not recoverable. This reality underscores why prompt evaluation and early treatment are so critical.
Some patients experience lasting vision changes, particularly if the macula or optic nerve was involved before treatment began. Low vision rehabilitation services can help patients make the most of their remaining vision. These services may include training with magnification devices, lighting and contrast adjustments, and strategies for daily activities.
A retina specialist can help connect patients with appropriate low vision and support resources suited to their specific level of visual function.
Ongoing monitoring is an essential part of care for anyone who has had CMV retinitis. Regular follow-up examinations allow our team to detect any reactivation early and respond before further damage occurs. Maintaining consistent adherence to antiretroviral therapy, immunosuppressive management, or other prescribed treatments is equally important in reducing the risk of recurrence.
Frequently Asked Questions
These answers are intended to address specific questions patients often have when navigating a CMV retinitis diagnosis and treatment process.
Yes, reactivation is possible, particularly if immune function declines again. The virus remains dormant in the body even after successful treatment. Patients who discontinue maintenance antiviral therapy or experience a drop in immune function need close monitoring. Routine follow-up examinations with a retina specialist are the most reliable way to catch any recurrence before significant new damage occurs.
CMV retinitis most often begins in one eye, but without effective treatment and immune recovery, it can eventually affect both eyes. The risk of the second eye becoming involved is highest in patients whose immune systems remain severely compromised. This is one reason why systemic antiviral therapy, which treats the whole body rather than just one eye, is preferred over local therapy alone in most situations.
Treatment for CMV retinitis is designed to stop the infection from spreading rather than to immediately restore lost vision. During the induction phase, the goal is to stabilize the borders of the infected area, typically within two to three weeks. Vision that was lost before treatment began will generally not return, but successful treatment prevents further destruction. Your retina specialist will track the edges of the infection at each visit to confirm the response to therapy.
For people with HIV, consistent use of antiretroviral therapy to keep CD4+ counts well above 50 cells per microliter is the most effective prevention. Transplant recipients may be prescribed antiviral prophylaxis during the period of highest risk after surgery. For all high-risk groups, regular screening eye examinations are a critical preventive measure because the infection can be detected and treated before symptoms or significant vision loss develop.
Without treatment, CMV retinitis spreads progressively across the retina, destroying more tissue with each passing week. The infection can eventually reach the macula and optic nerve, causing severe central vision loss. Advanced, untreated cases also carry a significant risk of retinal detachment, a condition where the retina separates from the back wall of the eye, which can cause total vision loss in the affected eye. Prompt treatment is essential to prevent these outcomes.
CMV retinitis requires evaluation and management by a retina specialist, a physician with fellowship-level training in diseases of the retina and vitreous. The diagnosis, imaging interpretation, intravitreal treatment, and long-term monitoring involved in managing this condition go beyond the scope of routine eye care. If your primary eye care provider suspects CMV retinitis, a prompt referral to a retina specialist is the appropriate next step.
Retina Care at The Eye Center
The Eye Center is proud to offer specialized retina care to patients throughout Northern Virginia, with our retina clinic based at the Lansdowne office. Our visiting retina specialists bring fellowship-trained expertise in vitreoretinal surgery, medical retina, and uveitis, supported by advanced imaging technology including OCT, fluorescein and ICG angiography, color fundus photography, and B-scan echography. If you or someone you care for is at risk for CMV retinitis or is experiencing vision changes, we encourage you to reach out to our team so we can help protect your sight with the care and attention you deserve.